{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:26:28Z","timestamp":1788607588196,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The CARES trial is a randomized controlled trial mandated by the FDA to compare the cardiovascular safety of febuxostat and allopurinol in the management of gout. About 6190 patients with gout and major cardiovascular disease, randomly assigned to allopurinol or febuxostat, were prospectively followed up for a median of 32 months. No difference was noted in the occurrence of the primary end-point event, a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization, but cardiovascular death was significantly more common in the febuxostat group (4.3%) as compared with the allopurinol group (3.2%) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.03).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Present guidelines on the management of gout should be revised in view of recent findings. Allopurinol could be recommended as the sole first-line urate-lowering drug (ULD) in patients with no contraindication. In patients contraindicated to allopurinol, uricosurics could be preferred to febuxostat as first-line ULDs in patients with cardiovascular disease\/risk factors and no history of uric acid stones.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000573","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T07:43:36Z","timestamp":1546242216000},"page":"152-158","source":"Crossref","is-referenced-by-count":35,"title":["The role of febuxostat in gout"],"prefix":"10.1097","volume":"31","author":[{"given":"Thomas","family":"Bardin","sequence":"first","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Lariboisi\u00e8re, APHP"},{"name":"Universit\u00e9 Paris Diderot"},{"name":"INSERM U 1132, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Lariboisi\u00e8re, APHP"},{"name":"Universit\u00e9 Paris Diderot"},{"name":"INSERM U 1132, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40265-015-0360-7","article-title":"Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-198611050-00001","article-title":"Clinical pharmacokinetics of allopurinol","volume":"11","author":"Murrell","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2016.09.020","article-title":"Efficacy and safety of febuxostat in 73 gouty patients with stage 4\/5 chronic kidney disease: a retrospective study of 10 centers","volume":"84","author":"Juge","year":"2017","journal-title":"Joint Bone Spine"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.ajkd.2016.07.001","article-title":"Febuxostat in hyperuricemic patients with advanced CKD","volume":"68","author":"Lim","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R7-20230829","first-page":"1859","article-title":"Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2018","journal-title":"Exp Ther Med"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R9-20230829","first-page":"1791","article-title":"Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone","volume":"33","author":"Iwanaga","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600\u200amg\/day versus benzbromarone 100\u2013200\u200amg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6\u200amg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2015.07.011","article-title":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","volume":"83","author":"Bardin","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0091270012439715","article-title":"Clinical risk factors for adverse events in allopurinol users","volume":"53","author":"Ryu","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B\u22175801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","article-title":"Racial disparities in the risk of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States","volume":"46","author":"Lu","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B\u221758:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3899\/jrheum.111161","article-title":"Febuxostat hypersensitivity","volume":"39","author":"Abeles","year":"2012","journal-title":"J Rheumatol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jcpt.12322","article-title":"Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"40","author":"Chou","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.amjmed.2016.08.042","article-title":"Cross-reactions between allopurinol and febuxostat","volume":"130","author":"Lien","year":"2017","journal-title":"Am J Med"},{"key":"R31-20230829","first-page":"251","article-title":"Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?","volume":"48","author":"Paschou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","article-title":"Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia","volume":"69","author":"Kojima","year":"2017","journal-title":"J Cardiol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R43-20230829","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201903000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:51:51Z","timestamp":1693291911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201903000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000573","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}